[(1S,3S,4S,5S,7S,9S,13S,14R,15R,16S,17R)-3,4,7-trihydroxy-9,11-dimethyl-16-[(E)-2-methylbut-2-enoyl]oxy-19-methylidene-11-azahexacyclo[12.3.2.01,13.04,9.05,12.05,17]nonadecan-15-yl] (E)-2-methylbut-2-enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(1S,3S,4S,5S,7S,9S,13S,14R,15R,16S,17R)-3,4,7-trihydroxy-9,11-dimethyl-16-[(E)-2-methylbut-2-enoyl]oxy-19-methylidene-11-azahexacyclo[12.3.2.01,13.04,9.05,12.05,17]nonadecan-15-yl] (E)-2-methylbut-2-enoate
• 化学式: C₃₁H₄₃NO₇
• 分子量: 541.7
• InChiKey: PISLVTVZMHAKFK-LYFBXLQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] SYNTHETIC PROCESS<br/>[FR] PROCÉDÉ DE SYNTHÈSE
  申请人：UNIV LIVERPOOL

  公开号：WO2015145143A1

  公开（公告）日：2015-10-01

  The present invention relates to a process for preparing substituted piperidine compounds and especially chiral substituted piperidine compounds. The process involves reacting a substituted pyridinium ion with an amine as defined herein, in the presence of a hydrogen donor, a catalysts and a suitable solvent.

  本发明涉及制备取代哌啶化合物，尤其是手性取代哌啶化合物的过程。该过程涉及在氢供体、催化剂和适当溶剂存在下，将取代吡啶离子与本文所定义的胺反应。
• BALLOON CATHETER WITH POLYMERIC BALLOON HAVING A SURFACE MODIFIED BY A PHOTOACTIVATION REACTION AND METHOD OF MAKING
  申请人：D'Onofrio Simone

  公开号：US20140378897A1

  公开（公告）日：2014-12-25

  A balloon catheter, in particular a balloon catheter for angioplasty, the balloon having an inner or outer surface modified by means of a photoactivation reaction.

  一个气球导管，特别是用于血管成形术的气球导管，该气球通过光活化反应改性内部或外部表面。
• Shellac and paclitaxel coated catheter balloons
  申请人：Eurocor Gmbh

  公开号：EP2243501A1

  公开（公告）日：2010-10-27

  The present invention relates to a method for coating catheter balloons preferably textured catheter balloons with the pharmacological agent paclitaxel and the biological and biodegradable polymer composition shellac and optionally further components. Moreover the present invention relates to paclitaxel and shellac coated catheter balloons obtained according to the coating methods disclosed herein as well as the use of such coated catheter balloons for the short time release of the pharmaceutically active agent paclitaxel for prophylaxis and treatment of restenosis especially restenosis caused by angioplasty. The coated catheter balloons can be used alone or in combination with a coated or uncoated stent crimped on the catheter balloon before or after the coating with shellac and paclitaxel.

  本发明涉及一种用药剂紫杉醇和生物可降解聚合物组合物虫胶以及可选的其他成分涂覆导管球囊（最好是纹理导管球囊）的方法。此外，本发明还涉及根据本文公开的涂层方法获得的紫杉醇和虫胶涂层导管球囊，以及使用这种涂层导管球囊短时间释放药理活性剂紫杉醇，以预防和治疗再狭窄，特别是血管成形术引起的再狭窄。涂层导管球囊可单独使用，也可与在涂覆虫胶和紫杉醇之前或之后压接在导管球囊上的涂层或未涂层支架结合使用。
• LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3502130A1

  公开（公告）日：2019-06-26

  Disclosed is a ligand regulated protein-protein interaction system based on a lipocalin-fold molecule comprising: (a) a lipocalin-fold molecule (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below, and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand, and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 µM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

  所公开的是一种基于脂钙蛋白折叠分子的配体调节蛋白质-蛋白质相互作用系统，该系统包括 (a) 脂钙蛋白折叠分子 (b) 低分子量为 1500 Da 或以下的脂钙蛋白-折叠配体，以及 (c) 脂钙蛋白-折叠结合相互作用伙伴、 其中脂钙素折叠分子可与脂钙素折叠配体结合；以及 其中与脂钙蛋白配体结合的脂钙蛋白-折叠分子与脂钙蛋白-折叠结合相互作用伙伴结合的亲和力比未与脂钙蛋白-折叠配体结合的脂钙蛋白-折叠分子的亲和力至少高 10 倍、 其中脂钙蛋白-折叠结合相互作用伙伴不是天然存在的蛋白质，它在任何脂钙蛋白-折叠配体存在下对任何天然存在的脂钙蛋白-折叠分子的亲和力小于10 µM。
• Multiple inflation endovascular medical device
  申请人：W. L. Gore & Associates, Inc.

  公开号：US10595874B2

  公开（公告）日：2020-03-24

  A medical device may include a catheter, an expandable member, a cover, and an actuator. The catheter may include a longitudinal axis, proximal and distal ends, and a cover lumen extending from the proximal to the distal end. The expandable member may include proximal and distal ends and may be disposed on a distal section of the catheter. The cover may include a first region that may be disposed along the expandable member, and a second region that may extend along a length of the catheter beyond the proximal end of the expandable member towards the proximal end of the catheter. A first end of the cover may invert into the cover lumen. The actuator may be coupled to the first end of the cover and configured to move the first end of the cover towards the proximal end of the catheter along the longitudinal axis of the catheter.

  医疗设备可包括导管、可扩张部件、盖和致动器。导管可包括纵轴、近端和远端，以及从近端延伸至远端的盖腔。可膨胀部件可包括近端和远端，并可设置在导管的远端部分上。盖子可包括沿可扩展部件布置的第一区域和沿导管长度超出可扩展部件近端向导管近端延伸的第二区域。盖子的第一端可倒转到盖子腔内。致动器可以耦合到盖子的第一端，并配置为沿导管的纵向轴线将盖子的第一端向导管的近端移动。